tbuckley/cabot-search huggingface dataset:
Diabetes for a Day
Authors: Jared Ellis
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A phase I trial of laromustine (VNP40101M) and temozolomide for patients with malignant gliomas in first relapse or progression.
Authors: J. J. Raizer, L. Rice, A. Rademaker, J. Chandler, K. Muro, R. M. Levy, S. A. Grimm
Journal: Journal of Clinical Oncology (2011)

2064 Background: Effective treatments for recurrent malignant gliomas are limited. MGMT is one of the mechanisms of resistance for malignant gliomas. Depletion of MGMT may improve antitumor activity by increasing activity of alkylators. We used this concept in performing a phase I trial of temozolomide (TMZ) and laromustine (chloretazine). Methods: Patients were enrolled in standard 3 x 3 phase I trial with goal of performing a phase II trial at the MTD. Patients were treated with TMZ at 75 mg/m2days 1-7 and then chloretazine at 100, 150, or 125mg/m2 on day 7 (2 hours after TMZ) of a 6 week cycle. Patients were treated until progression or intolerable side effects. Patients had MRI scans every 6 weeks with a physical exam and weekly CBC’s were performed. Results: A total of 14 pts were accrued (10 GBM, 3 AA and 1 AOA), 10 M and 4 F with a median age and KPS of 51 (25-68) and 90 (80-100). Median number of cycles was 1 (1-4). Dose level 100 mg/m2 had 7 pts with 1 grade 4 thrombocytopenia, dose level 150 mg/m2had5 pts with1 grade 4 thrombocytopenia and 1 grade 3 fatigue. Does level 125 mg/m2 had 2 pts with 1 grade 4 leukopenia and thrombocytopenia. 10 pts had PD after 1 cycles, 4 were removed for toxicity. 3 pts who did not progress had SD. PFS-6 was 7%. Conclusions: The optimal dose for phase II was felt to be TMZ 75 mg/m2 x 7days and chloretazine 100 mg/m2 on day 7. The main toxicity of this regimen attempting to take advantage of MGMT depletion strategy is myelosuppression; similar to other trials using this strategy.
A Randomized Phase III Trial of Low Dose Liposomal Amphotericin B (L-AmB) as Prophylaxis of Invasive Fungal Infections (IFI) in Neutropenic Patients (pts).
Authors: Olaf Penack, Stefan Schwartz, Peter Martus, Mark Reinwald, Martin Schmidt-Hieber, Eckhard Thiel, Igor W. Blau
Journal: Blood (2005)
CBIO-35THE ROLE OF Spt6 IN GLIOBLASTOMA MAINTENANCE AND THERAPEUTIC RESISTANCE
Authors: Rikke Darling Rasmussen, Elisabeth A. A. Obara, Kamilla E. Jensen, Jiri Bartek, Jane Skjøth-Rasmussen, Jiri Bartek, Petra Hamerlik
Journal: Neuro-Oncology (2015)

Glioblastoma multiforme (GBM) is among the most lethal of solid cancers in adults. It is associated with a median survival of only approximately 15 months despite aggressive radio- and chemotherapies and recurrence is inevitable. Despite recent advances in our understanding of this deadly disease, the molecular mechanism and/or genes that cause high recurrence rates and treatment resistance in GBM are poorly understood. Histone chaperones affect the structure of the chromatin and expression of genes through interaction with histones and RNA polymerase II (PolII). Spt6 is a highly conserved transcription elongation factor and histone chaperone that has been found to counteract tri- methylation of the histone variant H3, at various lysines, an otherwise epigenetic mark which is associated with repression of transcription. We have identified a novel role of Spt6 in glioblastoma cells. Our data show that siRNA-mediated knockdown of Spt6 in GBM cells results in decreased proliferation rates and progression through the cell cycle, increased levels of DNA damage (measured by γH2AX) as well as delayed capacity for DNA repair after exposure to ionizing radiation. Altogether, our data imply an important role of Spt6 in glioblastoma maintenance and therapeutic resistance.
Physical and Functional Interactions of Acute Myeloid Leukemia-1 with Hypoxia Inducible Factor-1α Protein.
Authors: Yun Yu, Zhen-Gang Peng, Mei-Yi Zhou, Shi-Hua Liao, Ying Huang, Ji-Hui Qiu, Li-Shun Wang, Shuo Dong, Guo-Qiang Chen
Journal: Blood (2006)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells
Authors: Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades
Journal: Blood (2008)
Fertility preservation: don’t forget the boys
Authors: Rod T Mitchell, Leena Nahata, Gwendolyn P Quinn
Journal: BMJ (2017)

Counselling about fertility and options for fertility preservation is imperative for young people undergoing potentially gonadotoxic treatments. Anderson and Davies highlight recent success using cryopreserved ovarian tissue.1 This experimental approach, coupled with established techniques such as embryo and oocyte freezing in females and semen cryopreservation for adult men, offers a realistic possibility for future fertility.2 However, no established options …
Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
Authors: Hedwig M Blommestein, Djamila E Issa, Marjolein Pompen, Cédric Révil, Mels Hoogendoorn, Peter Joosten, Sonja Zweegman, Peter C. Huijgens, Carin A. Uyl-de Groot
Journal: Blood (2012)
Bidirectional synaptic plasticity can explain bidirectional retrograde effects of emotion on memory
Authors: Bryan A. Strange, Ana Galarza-Vallejo
Journal: Behavioral and Brain Sciences (2016)

Emotional events can either impair or enhance memory for immediately preceding items. The GANE model explains this bidirectional effect as a glutamate "priority" signal that modulates noradrenaline release depending on arousal state. We argue for an alternative explanation: that priority itself evokes phasic noradrenaline release. Thus, contrasting E-1 memory effects are explained by a mechanism based on the Bienenstock-Cooper-Munro theory.
High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
Authors: Niels Weinhold, Shweta S. Chavan, Christoph Heuck, Owen W Stephens, Ruslana Tytarenko, Michael Bauer, Erich Allen Peterson, Timothy C. Ashby, Tobias Meissner, Caleb K. Stein, Donald Johann, Sarah K. Johnson, Shmuel Yaccoby, Joshua Epstein, Frits van Rhee, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Faith E Davies, Bart Barlogie, Gareth J Morgan
Journal: Blood (2015)
Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).
Authors: Jose F. Tomas, Carlos Montalban, Joaquin Martinez-Lopez, Jose Paz, Miguel Canales, Joaquin Diaz-Mediavilla, Pedro Sanchez Godoy, Alberto Fdez de Sevilla, Javier Penalver, MDolores Caballero, Elena Prieto, Jose Salar, Raquel de Ona, Javier de la Serna
Journal: Blood (2006)
Improving the Health of the United States With a “Winnable Battles” Initiative
Authors: Thomas R. Frieden, Kathleen Ethier, Anne Schuchat
Journal: JAMA (2017)

In this Viewpoint, former Centers for Disease Control and Prevention Director Thomas Frieden and colleagues review the Center’s 2010 Winnable Battles initiative, and discuss target areas where they met and fell short of their public health goals.
The Fluency Amplification Model supports the GANE principle of arousal enhancement
Authors: Claus-Christian Carbon, Sabine Albrecht
Journal: Behavioral and Brain Sciences (2016)

The GANE (glutamate amplifies noradrenergic effects) model described by Mather et al. offers a neurophysiological basis for the arousal mechanism which is essential for empirical aesthetics and Gestalt processing. More generally, the core principle of perception can be interpreted as a continuous processing of competing arousal states, yielding selective amplification and inhibition of percepts to deduce the meaning of a scene.
JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate
Authors: Yu Chen, Sirirat Surinkaew, Patrice Naud, Xiao-Yan Qi, Marc-Antoine Gillis, Yan-Fen Shi, Jean-Claude Tardif, Dobromir Dobrev, Stanley Nattel
Journal: Cardiovascular Research (2017)

Left-atrial (LA) fibrosis is an important feature of many atrial fibrillation (AF) substrates. The JAK-STAT system contributes to cardiac remodelling, but its role in AF is unknown. Here we investigated JAK-STAT changes in an AF-model and their potential contributions to LA-fibrosis.LA-remodelling was studied in dogs with heart failure (HF) induced by ventricular tachypacing (VTP, 240 bpm), and in mice with left-ventricular (LV) dysfunction due to myocardial infarction (MI). The selective STAT-3 inhibitor S3I-201 was administered to fibroblasts in vitro or mice in vivo (10 mg/kg/d, osmotic mini-pump). HF-dogs developed LA-selective fibrosis and AF-susceptibility at 1-week VTP. The mRNA-expression of platelet-derived growth factor (PDGF, a JAK-STAT activator) isoforms A, C and D, as well as JAK2, increased in LA fibroblasts from 1-week VTP. HF upregulated protein-expression of PDGF-receptor-β and phosphorylated (activated) signal transducer and activator of transcription 3 (STAT3) in LA. PDGF-AB stimulation of LA fibroblasts increased PDGFR-α, STAT3 and phosphorylated-STAT3 expression, as well as collagen-1 and fibronectin-1 protein secretion (by 1.6- to 20-fold), with smaller changes in LV fibroblasts. Phosphorylated-STAT3 and collagen upregulation were suppressed by the JAK2 inhibitor AG-490, PDGF receptor inhibitor AG1296 and STAT3-inhibitor SI3-201. In vivo S3I-201 treatment of MI-mice attenuated LA-fibrosis, LA-dilation and P-wave duration changes versus vehicle-control.HF activates the LA JAK-STAT system and enhances PDGF-signalling. JAK-STAT inhibition reduces the profibrotic effects of PDGF stimulation on canine fibroblasts in vitro while attenuating in vivo LA-fibrosis and remodelling in post-MI mice, suggesting that the JAK/STAT pathway contributes to LA-fibrogenesis and might be a potential target for LA-fibrosis prevention.
Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells
Authors: Stephanie Tsang Mui Chung, Dirk Geerts, Kim Roseman, Ashleigh Renaud, Linda Connelly
Journal: Molecular Cancer (2017)

It is widely recognized that inflammation promotes breast cancer invasion and metastasis. Given the complex nature of the breast tumor inflammatory microenvironment, much remains to be understood of the molecular mechanisms that govern these effects. We have previously shown that osteoprotegerin knockdown in breast cancer cells resulted in reduced invasion and metastasis. Here we present novel insight into the role of osteoprotegerin in inflammation-driven tumor progression in breast cancer by investigating the link between osteoprotegerin, macrophages and the potent pro-inflammatory cytokine Interleukin-1beta. We used human breast cancer cell lines to investigate the effects of Interleukin-1beta treatment on osteoprotegerin secretion as measured by ELISA. We analyzed public datasets containing human breast cancer genome-wide mRNA expression data to reveal a significant and positive correlation between osteoprotegerin mRNA expression and the mRNA expression of Interleukin-1beta and of monocyte chemoattractant protein CC-chemokine ligand 2. Osteoprotegerin, Interleukin-1beta and CC-chemokine ligand 2 mRNA levels were also examined by qPCR on cDNA from normal and cancerous human breast tissue. We determined the effect of Interleukin-1beta–producing macrophages on osteoprotegerin expression by co-culturing breast cancer cells and differentiated THP-1 macrophages. Immunohistochemistry was performed on human breast tumor tissue microarrays to assess macrophage infiltration and osteoprotegerin expression. To demonstrate that osteoprotegerin mediated functional effects of Interleukin-1beta we performed cell invasion studies with control and OPG siRNA knockdown on Interleukin-1beta-treated breast cancer cells. We report that Interleukin-1beta induces osteoprotegerin secretion, independent of breast cancer subtype and basal osteoprotegerin levels. Co-culture of breast cancer cells with Interleukin-1beta-secreting macrophages resulted in a similar increase in osteoprotegerin secretion in breast cancer cells as Interleukin-1beta treatment. Macrophage infiltration correlates with osteoprotegerin secretion in human breast tumor tissue samples. We show that osteoprotegerin secretion is regulated by Interleukin-1beta in a p38- and p42/44-dependent manner. We also demonstrate that osteoprotegerin knockdown represses Interleukin-1beta expression, Interleukin-1beta-mediated breast cancer cell invasion and MMP3 expression. These data indicate a novel role for osteoprotegerin as a mediator of inflammation- promoted breast cancer progression.
Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.
Authors: Gautam Borthakur, Hagop Kantarjian, Guillermo Garcia-Manero, Sherry Pierce, Elihu Estey
Journal: Blood (2007)
Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).
Authors: Anjali Advani, Eva Giné, Christian Gisselbrecht, Ama Rohatiner, Steven Rosen, Mitchell Smith, Joseph Boni, Chantal Lejeune, Hemant Patel
Journal: Blood (2005)
High-Throughput Ig Sequencing of Paired Blood and Spleen Samples Allows a Redefinition of Memory IgM Subsets in Humans
Authors: Davide Bagnara, Margherita Squillario, David Kipling, Thierry Mora, Aleksandra Walczak, Deborah K. Dunn-Walters, Jean-Claude Weill, Claude-Agnès Reynaud
Journal: Blood (2014)
RARE-03PRIMARY DURAL LYMPHOMA: SINGLE INSTITUTION STUDY OF TREATMENT AND OUTCOME
Authors: Macarena de la Fuente, Jesus Fabregas, Arnold Markoe, Izidore Lossos
Journal: Neuro-Oncology (2015)

BACKGROUND: Primary dural lymphoma (PDL) is a rare form of primary intracranial lymphoma. Clinical and radiographic presentation often suggest a meningioma. Pathology often shows a low grade B-cell marginal zone lymphoma (MZL). MZL is very radiosensitive to relatively low dose of RT. Previous series have reported a high risk for systemic recurrence. METHODS: A retrospective review of primary dural lymphoma treated at the University of Miami Heath System between 08/2004-10/2014. RESULTS: Eleven patients were identified. Six were women. Median age at diagnosis was 48 years (range: 30 to 68). The most frequent symptoms at presentation were seizure (40%), headache (40%) and cranial nerve palsies (37%). Brain-MRI showed a single extra-axial enhancing lesion in 9 patients and multiple in two. Work-up was negative for systemic and leptomeningeal disease in all patients. Two patients had a history of HIV at diagnosis. All patients underwent resection/biopsy with an initial diagnosis of meningioma. Pathology showed marginal zone B-cell lymphoma (MZL) in all patients. One patient refused RT and was treated with rituximab. Ten patients were treated with focal RT. One of these patients refused to continue RT after been treated with 16 Gy. All others received between 30.6 to 36 Gy. Nine patients achieved complete response (CR) and two were lost to follow-up. Median follow-up was 3.3 years (range, 0.7 to 10 years). No patient developed a systemic relapse. Two patients developed CNS recurrences. One of these patients had progression of disease after being treated with 16 Gy and had a second course of RT (36 Gy), achieving CR. Another patient was treated with bendamustine/rituximab at progression and achieved CR. All patients are alive. CONCLUSIONS: Patients with PDL have a good prognosis. CR can be achieved with relatively low dose focal RT. No systemic relapses were observed in our series.
Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
Journal: New England Journal of Medicine (1991)

Patients with congestive heart failure have a high mortality rate and are also hospitalized frequently. We studied the effect of an angiotensin-converting–enzyme inhibitor, enalapril, on mortality and hospitalizaron in patients with chronic heart failure and ejection fractions ≤0.35.
Influence of Bone Marrow Graft B Lymphocyte Subsets on Outcome after Transplantation from HLA-Identical Siblings.
Authors: David Michonneau, Regis Peffault de Latour, Raphael Porcher, Marie Robin, Marc Benbunan, Vanderson Rocha, Patricia Ribaud, Christelle Ferry, Agnes Devergie, Eliane Gluckman, Jean-Pierre Marolleau, Gerard Socie, Jerome Larghero
Journal: Blood (2008)
Are Electronic Cigarette Users at Increased Risk for Cardiovascular Disease?
Authors: Aruni Bhatnagar
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer
Authors: L. J. Goldstein, A. O’Neill, J. Sparano, E. Perez, L. Shulman, S. Martino, N. Davidson
Journal: Journal of Clinical Oncology (2005)

512 Background: AT is one of the most active regimens in ABC (response rates=44–83%). Methods: A Phase III Intergroup trial was completed to test adjuvant AT vs. AC. Women with 1–3 N + or N - and T-size > 1cm were randomized to four cycles of AT (60 mg/m2/60 mg/ m2) or AC (60 mg/m2/600 mg/m2) q 3 wk x 4. After chemotherapy, pts with ER + and/ or PR + received tam for 5 years. Patients were stratified by nodal, hormone receptor (ER+ PR+, ER+PR-, ER-PR+, ER-PR-, ER/PR unk) and menopausal status. The primary endpoint was DFS. With 2778 patients (including 10% ineligible), this study had 83% power to detect a 25% reduction in DFS failure hazard rate using AT(assuming a 78% 5-yr DFS on the AC arm). Results: 2952 pts were randomized between 7/30/98 and 1/21/00. 2889 were eligible and analyzable. Arms were balanced for age, hormone receptor, menopause, nodes, surgery, grade and T-size: median age 51; 64% ER +; 65% LN-; grade: 10% low, 38% int., 46% high; and median T-size - 2.0 cm. Febrile neutropenia occurred in 19%(AT) and 6%(AC). There were 3 treatment related deaths on the AT arm. There were 7 cases of MDS/AML on each arm. DFS/OS Results: As of 9/04, with a median follow-up of 53 mo, there were 197/1444 recurrences in the AT arm vs. 212/1445 in the AC arm and 104 deaths in the AT arm vs. 113 in the AC arm: HR (.95 CI) for OS = 1.09 (0.84–1.43), p=0.48. Conclusions: These results show a better than expected outcome with both regimens. At 53 mo. median follow-up, there is no difference in DFS or OS, although there are fewer events in the AT arm. Data for the subset analysis of prespecified stratifications: LN, menopause, and various ER/PR groups will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Aventis Aventis
CBM-15DYNAMICS OF CIRCULATING HYPOXIA MEDIATED miRNAs AND TUMOR RESPONSE IN HIGH-GRADE GLIOMA PATIENTS TREATED WITH BEVACIZUMAB
Authors: Tali Siegal, Hanna Charbit, Iddo Paldor, Bracha Zelikovitch, Tamar Canello, Anat Mordechai, Arriel Benis, Michael L. Wong, Andrew P. Morokoff, Andrew H. Kaye, Iris Lavon
Journal: Neuro-Oncology (2015)

BACKGROUND: Bevacizumab is an antiangiogenic agent which is approved for recurrent glioblastoma and is still under investigation in high-grade gliomas. It produces a high rate of radiologic response but this response should be interpreted with caution because it is related to normalization of permeable tumor vessels and not necessarily to a true anti-tumor effect. We previously demonstrated that four of the hypoxia-mediated-miRNAs (miR-210, miR-21, miR-10b and miR-196b), are up-regulated in gliomas as compared to normal brain. We hypothesized that the regulation and expression of these miRNAs will be altered in response to bevacizumab treatment and tested it prospectively. OBJECTIVES: To perform a longitudinal monitoring of the circulating miRNAs in patients exposed to bevacizumab treatment and to correlate it with tumor response. METHODS: 55 serum samples were prospectively collected from 15 high-grade glioma patients prior to bevacizumab treatment and longitudinally during treatment. The quantification of the 4 miRNAs was evaluated by real-time-RT-PCR using total RNA that was extracted from the serum. At each time point tumor response was assessed on MRI using FLAIR and contrast enhanced images as well as RANO criteria for tumor response. RESULTS: Serum quantification level of miR-210 and miR-196b did not differ in high-grade glioma patients from healthy controls while levels of miR-10b and miR-21 were significantly increased in untreated brain tumor patients. Throughout the period of bevacizumab treatment higher quantification levels were displayed for both miR-10b and miR-21 in the majority of patients when compared to pre-bevacizumab levels. Their quantification correlated negatively and significantly with changes in enhancing tumor diameters (R= -0.648, p < 0.0001). FLAIR images and RANO assessment did not correlate with the sum quantification of these miRNAs. CONCLUSIONS: Circulating miR-10b and miR-21 probably reflect the anti-angiogenic effect of therapy but their role as biomarkers for tumor response remains uncertain and requires further investigation.
Phase II Multicenter Trial To Evaluate the Safety and Efficacy of Low-Toxicity Treosulfan/Fludarabine Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
Authors: Jerzy Holowiecki, S. Giebel, D. Beelen, R. Trenschel, H. Wandt, K. Schaefer-Eckart, T. Ruutu, L. Volin, H. Einsele, G. Stuhler, L. Uharek, I. Blau, M. Bornhaeuser, A. Zander, N. Kroeger, J. Aschan, J. Wojnar, M. Markiewicz, M. Freund, J. Casper
Journal: Blood (2007)